AKTX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Akari Therapeutics PLC

NASDAQ | AKTX

0.79

USD

+$0.00

(

+0.00%

)

At Close (As of Sep 17, 2025)

$24.62M

Market Cap

0

P/E Ratio

0

EPS

$3.85

52 Week High

$0.57

52 Week Low

HEALTHCARE

Sector

AKTX Chart

Recent Chart
Price Action

AKTX Technicals

Tags:

AKTX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $17M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$1.6M
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$22M
Net Income -$20M

Revenue & Profitability

Earnings Performance

AKTX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $51M
Total Current Assets $3M
Cash And Cash Equivalents At Carrying Value $2.6M
Cash And Short Term Investments $2.6M
Inventory -
Current Net Receivables $201K
Total Non Current Assets $48M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $39M
Intangible Assets Excluding Goodwill $39M
Goodwill $8.4M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $152K
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $20M
Current Accounts Payable $12M
Deferred Revenue -
Current Debt -
Short Term Debt $3.3M
Total Non Current Liabilities $8.4M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt $3.3M
Long Term Debt Noncurrent -
Short Long Term Debt Total $3.3M
Other Current Liabilities $4.2M
Other Non Current Liabilities $383K
Total Shareholder Equity $22M
Treasury Stock -
Retained Earnings -$247M
Common Stock $5.3M
Common Stock Shares Outstanding $12K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$13M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $14K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $382K
Cashflow From Financing $11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$20M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$14K
Total Revenue $0
Cost Of Revenue $14K
Costof Goods And Services Sold $14K
Operating Income -$22M
Selling General And Administrative $9.7M
Research And Development $7M
Operating Expenses $17M
Investment Income Net -
Net Interest Income -$236K
Interest Income $8K
Interest Expense $244K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$1.6M
Income Before Tax -$20M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$20M
Comprehensive Income Net Of Tax -
Ebit -$20M
Ebitda -$22M
Net Income -$20M

AKTX News

AKTX Profile

Akari Therapeutics PLC Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Akari Therapeutics PLC is a clinical-stage biopharmaceutical company based in London, United Kingdom, specializing in the development of innovative therapies for autoinflammatory diseases targeting the complement and leukotriene pathways. With a robust pipeline of drug candidates, Akari is committed to addressing significant unmet medical needs within this therapeutic area. The company aims to leverage its scientific expertise and strategic partnerships to advance its therapies through clinical trials and ultimately bring transformative treatments to patients.

ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.95%
$92.98
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ETWO
0.00%
$3.30
ATCH
+87.36%
$1.62
NVDA
-2.62%
$170.29
PLUG
+19.04%
$2.00
CGBS
-39.47%
$0.03
CDT
+40.10%
$0.89
BITF
+5.53%
$3.05
SNAP
+3.23%
$7.99
NFE
+8.00%
$2.16
QBTS
+18.75%
$22.54
SPRC
+142.93%
$4.47
NIO
+6.05%
$7.44
GRAB
-3.48%
$6.10
TSLA
+1.00%
$425.86
AAL
+0.84%
$12.51
LYFT
+13.12%
$22.84
GV
+68.16%
$2.80
NUAI
-4.00%
$0.45
MARA
-1.08%
$17.34
SOUN
+3.25%
$15.16
SOFI
-1.02%
$27.14
RGTI
+9.92%
$21.98
TPIC
-45.91%
$0.12
PLTR
-1.13%
$168.33
DNN
+1.60%
$2.54
AXDX
-61.36%
$0.03
ADAP
-1.22%
$0.08
BBD
+2.95%
$3.30
INTC
-1.46%
$24.90
PGRE
-11.43%
$6.54
F
+0.52%
$11.67
BMNR
+1.98%
$57.04
TNMG
-0.27%
$0.32
IPM
+22.79%
$2.37
LYT
-16.77%
$0.09
BTG
+0.23%
$4.33
JOBY
-1.59%
$14.16
MULN
-12.58%
$0.06
WBD
-1.42%
$17.98
RR
+2.84%
$3.98
NAKA
-4.66%
$1.43
KDLY
-4.66%
$1.43
RIVN
-1.46%
$14.11
AAPL
+0.35%
$238.99
PFE
+0.62%
$24.05
AVGO
-3.84%
$346.17
UBER
-4.95%
$92.98
AMZN
-1.03%
$231.62
AIRE
-1.57%
$1.25
ACHR
-1.20%
$9.00
ONDS
+0.16%
$6.10
QS
+1.08%
$10.26
IONQ
+4.97%
$65.36
ABEV
0.00%
$2.36
LDI
+2.70%
$4.55
RIOT
+0.82%
$17.66
BINI
-6.96%
$0.06
RMBL
+60.50%
$3.21
WULF
+3.74%
$11.35
ADD
-25.47%
$0.05
RELI
+6.58%
$0.72
OPI
-31.80%
$0.56
TLRY
-2.45%
$1.19
AMD
-0.60%
$159.49
ETHD
-1.52%
$3.22
SRM
+53.27%
$10.30
VALE
-0.27%
$10.88
HOOD
+1.07%
$118.64
DVLT
-22.98%
$0.34
NOK
+1.84%
$4.69
QUBT
+4.97%
$17.71
CIFR
+7.55%
$12.38
GOOGL
-0.64%
$249.53
IREN
+3.97%
$37.90
NWTN
+12.58%
$1.70
CWD
+19.05%
$7.56
ATYR
-5.09%
$1.02
JD
+1.52%
$35.24
FAAS
-6.04%
$0.09
ITUB
+1.82%
$7.27
INFY
+3.60%
$17.67
RZLV
-3.60%
$7.08
RIG
-1.87%
$3.40
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
BABA
+2.44%
$166.17
KEY
+0.42%
$18.71
BAC
+1.41%
$51.37
BTE
-2.49%
$2.54
IONZ
-10.28%
$4.80
WLGS
-5.57%
$0.04
CLSK
+2.14%
$11.44
BURU
-0.86%
$0.13
T
-0.97%
$29.33
HBAN
+0.63%
$17.54
JBLU
0.00%
$5.07
GDXD
+1.63%
$1.24
RAYA
-4.69%
$0.04
HIMS
-1.06%
$50.35
CAN
+0.23%
$0.80
ETWO
0.00%
$3.30
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.